Gregery K Lester, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 16342 Third St #2, Guerneville, CA 95446 Phone: 707-869-8123 |
News Archive
A new study published in The Lancet compares outcomes for two drugs used to prevent blood clot formation during emergency heart attack treatment. The study suggests that use of one of the drugs, heparin, could result in improved outcomes (such as a reduced rate of repeat heart attacks), compared to the other drug tested, bivalirudin, which is in widespread use in high-income countries, and is around 400 times more expensive than heparin.
In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.
More than half of all countries worldwide are struggling to prevent cancer and provide treatment and chronic care to cancer patients, warns a recent World Health Organization (WHO) survey for World Cancer Day. This means, currently many of these countries do not have a functional cancer control plan that includes prevention, early detection, treatment and care. There is an urgent need to help countries to reduce cancer deaths and provide appropriate long-term treatment and care to avoid human suffering and protect countries' social and economic development.
TriLink BioTechnologies (TriLink), has entered into an agreement with Nacalai USA, Inc., a San Diego based manufacturing and marketing company, for the distribution of TriLink's modified nucleic acid products in Japan, Singapore, South Korea and Taiwan.
› Verified 6 days ago